非酒精性脂肪性肝炎 (NASH) 治療和診斷市場：按治療、診斷和地區分類。

Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics, By Diagnostics, and By Geography -

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

非酒精性脂肪性肝炎 (NASH) 治療和診斷市場預計在 2026 年達到 304.809 億美元，預計在 2033 年達到 1,113.385 億美元。預計從 2026 年到 2033 年，該市場將以 20.3% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	304.809億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	20.30%	2033年市場規模預測：	1113.385億美元

非酒精性脂肪性肝炎（NASH）是由脂肪細胞過多（脂肪肝）引起的肝臟發炎。過多的脂肪會導致肝臟發炎（腫脹）和纖維化（疤痕形成），最終發展為NASH。 NASH被認為是一種“隱性流行病”，因此，人們對安全有效的治療方法和診斷方法的需求日益成長。

市場動態

NASH 患者數量的增加、糖尿病和肥胖人口的成長、對安全有效的 NASH 治療和診斷的需求不斷成長、政府和非政府組織的支持措施以及對 NAFLD/NASH 的認知不斷提高，這些因素預計將在預測期內推動全球非酒精性脂肪性肝炎 (NASH) 治療和診斷市場的成長。

例如，2022年6月，Echosens和諾和諾德公司宣佈建立合作夥伴關係，旨在促進非酒精性脂肪性肝炎（NASH）的早期診斷，並提高患者、醫療專業人員和其他相關人員對該疾病的認知。 2018年6月，全球肝臟研究所設立了第一個“國際NASH日”，以提高人們對NASH的認知，並宣傳人們可以採取哪些措施來預防該疾病。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據公司概況、產品系列、主要亮點、財務表現和策略等參數，介紹了全球非酒精性脂肪性肝炎 (NASH) 治療和診斷市場主要參與者的概況。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球非酒精性脂肪性肝炎 (NASH) 治療和診斷市場」報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用全球非酒精性脂肪性肝炎 (NASH) 治療和診斷市場分析中使用的各種策略矩陣來簡化決策過程。

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 30,480.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	20.30%	2033 Value Projection:	USD 1,11,338.5 Mn

Non-alcoholic steatohepatitis (NASH) is inflammation of the liver caused by excess fat cells in it (fatty liver disease). It is caused when that extra fat turns into inflammation (swelling in the liver) and fibrosis (scarring) of the liver. NASH is a hidden epidemic, and thus, there is an increase demand for safe and effective therapeutics and diagnostics.

Market Dynamics:

Rise in NASH-affected population, increase in diabetic and obese population, increase in demand for safe and effective NASH therapeutics and diagnostics, favorable initiatives by government and non-government organizations, and increasing awareness about NAFLD/NASH are major factors expected to propel the growth of the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market during the forecast period.

For instance, in June 2022, Echosens and Novo Nordisk A/S announced a collaboration to advance the early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers, and other stakeholders. In June 2018, the first International NASH Day was launched by Global Liver Institute with the goal of raising awareness about NASH and the actions people can take to prevent the disease.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market.

Detailed Segmentation:

Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics (Revenue, USD Mn, 2021 - 2033)
Elafibranor
Ocaliva
Selonsertib
Cenicriviroc
Emricasan
Other Therapeutics
Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Diagnostics (Revenue, USD Mn, 2021 - 2033)
Imaging Techniques
Diagnostic Tests
Biopsy
Regional Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles:
Novartis AG
Allergan Plc.
Viking Therapeutics
Merck & Co.
Zydus Cadila
Novo Nordisk A/S
GENFIT SA
Gilead Sciences Inc.
Galmed Pharmaceuticals
Madrigal Pharmaceuticals
Intercept Pharmaceuticals Inc.

Market Dynamics
- Rise in NASH-affected population worldwide
- Slow advancements in the therapeutic field
- Rise in demand for safe/effective therapeutics and diagnostics
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Elafibranor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Ocaliva
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Selonsertib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Cenicriviroc
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Emricasan
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Other Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

5. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Diagnostics, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Imaging Techniques
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Diagnostic Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Biopsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

6. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Geography, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)

7. Competitive Landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Allergan Plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viking Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GENFIT SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gilead Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Galmed Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Madrigal Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Intercept Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views